{"Clinical Trial ID": "NCT01015131", "Intervention": ["INTERVENTION 1:", "All participants", "Participants with 18 FLT positron emission tomography (PET) and standard neo-adjuvant chemotherapy (SOC)"], "Eligibility": ["Incorporation criteria:", "Recently diagnosed Stage IIB/IIIA/IIIB locally advanced breast cancer", "Is eligible for pre-operative chemotherapy (neoadjuvant)", "- Exclusion criteria:", "A contraindication to magnetic resonance imaging (MRI)", "Any condition that would limit the ability to undergo MRI or PET scans", "\u266a Is a nursing mother \u266a", "- Moderate to terminal renal impairment and is not dialysis or has chronic renal impairment"], "Results": ["Performance measures:", "Change from baseline in 18F-FLT-PET Standardized Average Management Value (SUVmedium) After the first cycle of Standard of Care (SOC) neo-adjuvant chemotherapy.", "Participants undergo a basic 18F-FLT-PET/CT scan followed by a magnetic resonance imaging (MRI) scan prior to chemotherapy. These scans are repeated in approximately 2 to 3 weeks at the end of the first chemotherapy cycle to obtain a standardized absorption value (SUV) of 18F-FLT, calculated from the radioactivity concentration ratio in a region of interest, and the dose injected at the time of injection, divided by body weight.", "Time frame: Baseline and up to 3 weeks", "Results 1:", "Title of the arm/group: All participants", "Description of the arm/group: Participants with 18 FLT (PET) positron emission tomography and standard neoadjuvant chemotherapy (SOC)", "Total number of participants analysed: 36", "Average (standard deviation)", "Unit of measure: SUV Reference: 2.79 (1.36)", "At the end of cycle 1: 1.78 (1.03)", "Change from baseline: 1.00 (0.95)"], "Adverse Events": ["Undesirable Events 1:", "Total: 8/44 (18.18 per cent)", "- Febrile neutropenia4/44 (9.09%)", "Rectal haemorrhage1/44 (2.27%)", "Thoracic pain2/44 (4.55%)", "Fever1/44 (2.27 per cent)", "Infection at the catheter1/44 site (2.27%)", "Decrease in the number of neutrophils1/44 (2.27 per cent)", "Dizzying sensations1/44 (2.27%)"]}